



[12] Patent

[11] Patent No.: GC 0000117	Number of the Decision to Grant the Patent: 5/2
[45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005	Date of the Decision to Grant the Patent: 15/03/2005
[21] Application No.: GCC/P/1999/452 [22] Filing Date: 21/12/1999 [30] Priority: [31] Priority No. [32] Priority date [33] State 9828420.1 23/12/1998 GB 9921375.3 10/09/1999 GB [72] Inventors: 1- Duncan Robert Armour, 2- David Anthony Price, 3- Blanda Luzia Christa Stammen, 4- Anthony Wood, 5- Manoussos Perros, 6- Martin Paul Edwards [73] Owner: Pfizer Inc., 235 East 42nd street, New York, New York 10017, USA [74] Agent: Nassir Ali Kadasa	[51] Int. Cl. ⁷ : A61K 31/445; C07D 451/04; A61K 31/46 [56] Cited Documents: - WO 99/04794 A (MERK & CO., INC.) 04 February 1999 - WO 98/25605 A (MERK & CO., INC.) 18 June 1998 - WO 98/25604 A (MERK & CO., INC.) 18 June 1998 - WO 98/02151 A (LEUKOSITE, INC.) 22 January 1998 - WO 98/25617 A (MERK & CO., INC.) 18 June 1998 - EP 0630887 A (ZENECA LTD.) 28 December 1994 - WO 97/24325 A (TAKEDA CHEMICAL INDUSTRIES, LTD.) 10 July 1997 - EP 0903349 A (F. HOFFMANN-LA ROCHE AG) 24 March 1999 - WO 97/19060 A (ZENECA LTD.) 29 May 1997 - WO 99/37619 A (LEUKOSITE, INC.) 29 July 1999 - WO 99/37617 A (LEUKOSITE, INC.) 29 July 1999 - WO 99/17773 A (SMITHKLINE BEECHAM CORPORATION) 15 April 1999 - WO 96/24582 A (ZENECA LTD.) 15 August 1996

[54] CCR5 MODULATORS

[57] Abstract: Compounds of Formula 1

[Region α] - [Region β] - [Region γ] - [Region δ] (1)

which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.

No. of claims: 31